Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

The peptide structure of Tirzepatide includes modifications that are believed to increase its stability and extend its activity, potentially leading to more sustained metabolic impacts.

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

In a new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for ...

Tirzepatide combined with lifestyle modification reduced the highest number of obesity cases (45,609 per 100,000 eligible individuals), diabetes cases (20,854 per 100,000 eligible individuals ...

1 This denial keeps in place the FDA’s declaratory order determining that the shortage of diabetes and weight-loss tirzepatide products has been resolved and phases out compounded tirzepatide ...

Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model. A multifaceted approach is needed to reduce financial barriers to obesity ...

Lexaria Bioscience (LEXX) announced pharmacokinetic results from Human Study #3 or GLP-1-H24-3, comparing an oral version of ...